In the Illawarra Shoalhaven Local Health District, over 2600 new cases of cancer are diagnosed each year. The most common cancer types afflicting residents are prostate, breast and lung cancers.
Our researchers work tirelessly to improve the diagnosis and treatment of patients with cancer by endeavouring to understand the disease at a molecular level.
The Illawarra Health and Medical Research Institute (IHMRI), located at the Wollongong campus, provides support and medical research for the Illawarra Shoalhaven area to find new insights into disease and illnesses as well as prevention strategies.
We are committed to working with our researchers and communities to ensure access to resources for cancer patients in the region.
As the population of the Illawarra Shoalhaven Local Health District increases, the challenge is to decrease the rate of new cancer cases and reduce the impact of the disease on patients already diagnosed.
Professor Philip Clingan and Professor Marie Ranson have worked to develop Deflexifol, a chemotherapy drug that has shown positive early results in patients with colorectal, breast and lung cancers. They took a 50-year-old drug and reformulated it to solve common problems with its administration and level of toxicity. Prof Clingan says the team believes patients using Deflexifol will have better quality of life and higher survival rates than those using currently available chemotherapy drugs.
With your support, Deflexifol can move beyond the trial phase to help more cancer patients. Prof Clingan says early trials have found the optimum dose of the Deflexifol for use in patients who have failed all prior treatment.
Professors Clingan and Ranson are working with their team on a range of cancer treatments. Your support will accelerate their progress towards a better treatment or even a cure.
Our track record
UOW alumni, Illawarra community members and the charitable organisation Illawarra Cancer Carers have given generously to support our cancer research. This year the Illawarra Cancer Carers reached a milestone as its donations to the University reached $1million.
This support allowed the UOW to purchase a Nanostring machine, equipment that enables researches to significantly reduce the time it takes to collect genetic data for cancer research.
Illawarra cancer patients have been the first in the world to trial the new drug which proved to be more effective and less toxic than other chemotherapy drugs available.
Some patients in the trial were told they had only months to live, but Deflexifol kept their cancer under control for a significant period of time and one patient went into remission.
Prof Clingan said Deflexifol would have have remained on the shelf as a good but untested idea without the generosity of the local community through donations and the assistance of the Illawarra Cancer Carers